Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New ulcer drug formulations tested in healthy adults

NCT ID NCT06902818

Knowledge-focused Sponsor: Addpharma Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tested two different tablet versions of a drug for gastric ulcers in 46 healthy adults. Participants received a single dose of each formulation on separate occasions to compare how the drug moves through the body and to check for side effects. The goal is to see which version works better and is safer before testing in patients with ulcers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AD-115A and AD-1151 (oral tablets for gastric ulcer)
What this could lead to
If successful, this study could help determine which formulation is better absorbed and safer, potentially leading to an improved treatment option for gastric ulcers.
What could go wrong
This is a very early Phase 1 trial in only 46 healthy people, not patients with ulcers. It only measures drug levels and short-term safety, not whether the drug actually heals ulcers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

46 people

The number who actually took part.

Started

Mar 2025

Finished

May 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The Age equal to or greater than 19 in healthy volunteers at the time of screening visit * Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit Exclusion Criteria: * Individuals who have taken drugs that induce (e.g., barbiturates) or inhibit drug-metabolizing enzymes within 30 days prior to the start of the study (first dosing day), or have taken drugs that may affect this study within 10 days prior to the start of the study (first dosing day) * Other exclusions applied

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric ulcer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric ulcer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric ulcer

Contacts and locations

Locations

  • H PLUS YANGJI HOSPITAL, Seoul,

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.